An intraductal papillary mucinous neoplasm (IPMN) is a type of cyst that grows inside the ducts of your pancreas and produces a thick, gel-like substance called mucin. IPMNs are important because they can, over time, develop into pancreatic cancer. Most are found incidentally during imaging done for unrelated reasons, and the majority never become cancerous, but they require monitoring because a meaningful minority do progress.
How IPMNs Form and Cause Problems
Your pancreas has a network of ducts that carry digestive enzymes into your small intestine. An IPMN is a growth on the lining of these ducts that produces excess mucin. As mucin builds up, it can clog the ducts and cause them to dilate, much like a slow drain backing up a pipe. This blockage is what leads to most symptoms: it can trigger episodes of pancreatitis (painful inflammation of the pancreas) or, if the cyst is in the head of the pancreas, it can press on the bile duct and cause jaundice, a yellowing of the skin and eyes.
Many people with IPMNs have no symptoms at all. The cyst is often spotted on a CT scan or MRI that was ordered for something else entirely, like back pain or a kidney issue. When symptoms do appear, they tend to include abdominal pain, nausea, or unexplained weight loss.
The Three Types and Why They Matter
IPMNs are classified by where they grow within the pancreatic duct system. This distinction is critical because it directly determines cancer risk and whether surgery is needed.
Main duct IPMNs involve the central channel of the pancreas. Think of it as a growth in the trunk of a tree. These carry the highest risk: malignancy (including both pre-cancerous and invasive cancer) is found in roughly 60% to 92% of cases, with an average around 70%. Because of this, surgical removal is recommended for virtually all main duct IPMNs in patients healthy enough for the operation.
Branch duct IPMNs form in the smaller side channels that feed into the main duct. Think of a growth on a branch of the tree. These are far more common and significantly less dangerous. Malignancy rates range from 6% to 46%, with an average around 25%, and truly invasive cancer is found in about 15% on average. Many branch duct IPMNs can be safely watched over time rather than removed.
Mixed (combined) IPMNs involve both the main duct and one or more branches. Their cancer risk falls between the other two types, with malignant elements found in about 62% of cases and invasive cancer in roughly 42%.
How IPMNs Are Diagnosed
The two most important imaging tools are MRI with a specialized protocol called MRCP and endoscopic ultrasound (EUS). MRCP is non-invasive and serves as the primary way to detect and monitor pancreatic cysts. It’s particularly useful for tracking smaller branch duct IPMNs over time. Doctors look for specific warning signs on imaging: a main pancreatic duct wider than 5 mm, mural nodules (small solid bumps growing inside the cyst wall), and whether the cyst communicates with the main duct.
When more detail is needed, endoscopic ultrasound provides higher-resolution images. A thin, flexible scope is passed through your mouth into your stomach, where an ultrasound probe can image the pancreas from just millimeters away. This is the most sensitive method for spotting mural nodules. During the same procedure, doctors can insert a fine needle into the cyst to collect fluid for analysis, checking for abnormal cells and tumor markers that help distinguish harmless cysts from worrisome ones.
Cancer Risk Over Time
Not every IPMN becomes cancer, but the risk isn’t zero, and it accumulates over the years. A large meta-analysis found that low-risk IPMNs (those without worrisome features) have about an 8% chance of progressing to pancreatic cancer within 10 years. Higher-risk IPMNs, those with features like larger size or duct dilation, have roughly a 25% chance of becoming cancer over the same period.
This is why long-term surveillance matters even when an IPMN looks benign at first. The risk doesn’t disappear after a few clean scans.
When Surgery Is Recommended
International guidelines identify specific “high-risk stigmata” that signal a strong likelihood of cancer and call for surgical removal. These include:
- Obstructive jaundice in someone with a cyst in the head of the pancreas
- Mural nodules of 5 mm or larger visible on imaging
- Main pancreatic duct dilation of 10 mm or more
- A solid mass in the pancreatic tissue adjacent to the cyst, which may indicate the tumor has already become invasive
For branch duct IPMNs, surgery is also recommended when the cyst is larger than 3 cm, causes symptoms like pancreatitis, or grows rapidly (5 mm or more per year). Additional red flags include rising levels of a blood marker called CA 19-9 and new-onset diabetes, which can signal that a pancreatic tumor is affecting the organ’s ability to regulate blood sugar.
The type of surgery depends on where the IPMN is located. A cyst in the head of the pancreas requires removal of that portion of the organ, while one in the tail involves removing the tail. In rare cases where the IPMN spans the entire length of the pancreas, the whole organ may need to be removed.
Survival After Surgery
Outcomes depend heavily on whether cancer has already developed at the time of surgery. Non-invasive IPMNs, those that haven’t yet progressed to cancer, are generally considered curable with surgery. The main caveat is that new IPMNs can form in the remaining pancreatic tissue over time, a phenomenon called a “field defect,” meaning the entire pancreas may have a tendency toward these growths.
When an IPMN has already become an invasive cancer, outcomes are more guarded but still far better than typical pancreatic cancer. Even patients with small IPMN-associated cancers (invasive component of 20 mm or less) have a five-year survival rate of about 59%. This compares favorably to standard pancreatic cancer, where five-year survival is well under 15%, highlighting the value of catching these growths through surveillance before they advance.
What Surveillance Looks Like
If your IPMN doesn’t meet criteria for surgery, you’ll enter a monitoring schedule. European guidelines recommend imaging every six months during the first year after diagnosis, then annually after that, assuming no new warning signs develop. Cysts measuring 15 mm or larger follow this same timeline. If your IPMN has borderline features that don’t quite require surgery, or if you have health conditions that make surgery risky, your doctor will likely keep you on the more frequent six-month schedule indefinitely.
During surveillance, your care team watches for changes in cyst size, the appearance of new nodules, widening of the main duct, new symptoms, and changes in blood markers. Any of these can shift the recommendation from watching to operating. The goal of this entire process is to intervene before an IPMN becomes invasive cancer, when the chances of a cure are highest.